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The relative efficiency of time-to-progression and continuous measures
of cognition in presymptomatic Alzheimer’s diseaseDan Lia, Samuel Iddia,b, Paul S. Aisena, Wesley K. Thompsonc, Michael C. Donohuea,*,
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license (http://creativerate of disease progression. We use a simulation study to demonstrate that models of repeated cogni-
tive assessments detect treatment effects more efficiently than models of time to progression.
Methods: Multivariate continuous data are simulated from aBayesian jointmixed-effectsmodel fit to
data from the Alzheimer’s Disease Neuroimaging Initiative. Simulated progression events are algo-
rithmically derived from the continuous assessments using a random forest model fit to the same data.
Results: We find that power is approximately doubled with models of repeated continuous outcomes
compared with the time-to-progression analysis. The simulations also demonstrate that a plausible
informative missing data pattern can induce a bias that inflates treatment effects, yet 5% type I error
is maintained.
Discussion: Given the relative inefficiency of time to progression, it should be avoided as a primary
analysis approach in clinical trials of preclinical Alzheimer’s disease.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Clinical trial simulations; Alzheimer’s disease; Cox proportional hazards model; Longitudinal data; Mixed modelof repeated measures (MMRM); Statistical power; Common close design; Bayesian joint mixed-effect model1. Introduction
Presymptomatic (or preclinical) Alzheimer’s disease
(PAD) is defined by evidence of abnormal levels of fibrillar
amyloid beta (Ab) in brain as measured by positron emis-
sion tomography brain scan or cerebrospinal fluid (CSF)
assay [1]. Clinical trials have been initiated in this earlyest: The authors declare no potential conflicts of
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).phase of disease with the hope that, as in other diseases,
early interventions will be more successful in slowing pro-
gression [2–4].
InPAD,progression is typicallymeasuredbycontinuousas-
sessments such as the Preclinical Alzheimer’s Cognitive Com-
posite (PACC), a cognitive performance assessment sensitive
to amyloid-related decline [5]. An alternative measure of pro-
gression is transition from normal cognition to mild cognitive
impairment (MCI). The diagnosis ofMCI is not algorithmic. It
is based on an expert clinician’s subjective impression of clin-
ical tests and interviews with participants or study partners. In
contrast to cancer progression or death, the cognitive diagnosis
(normal orMCI) canvary fromone clinician to the next or from
one study visit to the next. In a multicenter study, the diagnosis
made by a clinician at a trial performance site may be
confirmed by experts centrally based on review of assessments
without the benefit of direct in-person assessment.imer’s Association. This is an open access article under the CC BY-NC-ND
Table 1
Descriptive statistics by baseline diagnosis, normal cognition (NC), and subjectivememory concern (SMC) for the preclinical Alzheimer’s disease population in
the Alzheimer’s Disease Neuroimaging Initiative
Variable NC (N 5 120) SMC (N 5 43) Total (N 5 163)
Age 75.21 (5.83) 72.77 (5.78) 74.57 (5.90)
APOE ε4 alleles
0 52 (43) 23 (53) 75 (46)
1 111 (57) 140 (47) 88 (54)
ADAS delayed word recall 2.96 (1.79) 3.00 (2.08) 2.97 (1.86)
Logical memory—delayed recall 13.11 (3.15) 12.63 (3.19) 12.98 (3.16)
Trails B 93.40 (48.90) 89.10 (32.00) 92.30 (45.00)
MMSE 29.11 (1.13) 29.09 (0.89) 29.10 (1.07)
Category fluency (animals) 20.72 (5.32) 19.72 (5.60) 20.45 (5.40)
CDRSB
0 111 (92) 36 (84) 147 (90)
0.5 8 (7) 7 (16) 15 (9)
1 1 (1) 0 (0) 1 (1)
FAQ
0 108 (90) 32 (74) 140 (86)
1 7 (6) 8 (19) 15 (9)
2 2 (2) 0 (0) 2 (1)
3 2 (2) 3 (7) 5 (3)
5 1 (1) 0 (0) 1 (1)
NOTE. Values are given as count (%) or mean (SD).
Abbreviations: ADAS, Alzheimer’s Disease Assessment Scale; APOE, apolipoprotein E;MMSE,Mini-Mental State Examination; CDRSB, Clinical Demen-
tia Rating—Sum of Boxes; FAQ, functional assessment questionnaire; SD, standard deviation.
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ness of time-to-MCI analysis. Undoubtedly, for a given sub-
ject, a transition from normal cognition to MCI is more
clinically meaningful than a point change in a continuous
cognitive performance measure. However, in a clinical trial,
we are still left to determine how large a randomized group
difference in the rate of, or delay in, a clinically meaningful
event is itself clinically meaningful.
The typical Alzheimer’s clinical trial assesses cognition
at clinic visits conducted every three or six months. With a
continuous outcome, the primary contrast is estimated at
the last scheduled visit, at approximately 4.5 years. Propo-
nents of time to progression argue that the endpoint allows
for a common close design, similar to oncology studies, in
which follow-up can continue until the last subject enrolled
reaches the 4.5-year visit. The Cox Proportional Hazards
model [6] admits data collected under such a design. Linear
mixed-effects models can also admit data from a common
close design, but assumptions about the mean trend (e.g.,
quadratic time trends) are necessary, similar to the propor-
tional hazards assumption.
Some related work has demonstrated the advantages of
analyzing continuous outcomes, when available, over
time-to-event outcomes in other contexts. Donohue et al.
[7] reviewed the literature and provided an analytic demon-
stration that, under general conditions, a mixed-effect model
comparison of rate of change on a continuous outcome is
effectively always more powerful than an analysis of time
to threshold. The authors also conducted simulations based
on Alzheimer’s Disease Neuroimaging Initiative (ADNI)
MCI subjects and demonstrated that the marginal linearmodel and linear mixed models are more robust and efficient
than the Cox model of time from MCI to dementia.
Our goal is to extend our earlier work in the MCI popula-
tion [7] to the earlier biomarker-defined PAD population.
Specifically, we aim to compare the performance of models
of repeatedmeasures of the PACC versus time to progression
when evaluating treatment effects in randomized trials and
to assess bias due to informative missingness. We also
compare the common close design and the fixed follow-up
design. We apply the mixed models of repeated measures
(MMRMs) [8] for the analysis of change in the PACC score.
Constrained longitudinal data analysis (cLDA) models [9]
are also used to model the PACC scores, treating time as a
continuous variable. Cox proportional hazards model is
applied to the time-to-event endpoint.2. Data
ADNI is a prospective observational cohort study, led by
principal investigator Michael W. Weiner, MD, which is
tracking cognitive, imaging, and biofluid markers of Alz-
heimer’s in volunteers diagnosed as cognitively normal
(CN), with subjective memory concern, MCI, and mild-to-
moderate dementia. To simulate both longitudinal contin-
uous markers and time to MCI for a PAD clinical trial, we
first model the disease markers and clinical diagnosis using
data from PAD ADNI participants. The PAD population is
defined by a diagnosis of CN or subjective memory concern
at baseline and florbetapir positron emission tomography
standardized uptake value ratio above 1.11 [10] or CSF Ab
below 950.6 pg/ml. The CSF threshold of 950.6 pg/ml
Table 2
Missing data patterns assumed in simulations
Scenario Missing data rate
Group Treatment
Perceived
inefficacy Intolerability
Completely at
random
Active Ineffective 15% 10% 5% per year
Active Effective 8% 10% 5% per year
Placebo Not
applicable
15% 0% 5% per year
Participants having intolerability are simulated to drop out at month six,
and those perceiving inefficacy drop out at twelve months.
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the 1.11 standardized uptake value ratio threshold. Follow-
up observation reports, including a site clinician’s diagnosis
of CN, MCI, or dementia, are collected every three, six, or
12 months. For more information on the study design of
ADNI, including protocols, see adni.loni.usc.edu.
Sensitive tests of cognition may show changes in PAD
many years before the onset of functional decline [5,11].
In this work, we focus on the following seven cognitive
outcomes in the PAD population:
1. Alzheimer’s Disease Assessment Scale delayed word
recall (ADASDWR) [12],
2. Logical memory paragraph recall (LogMem) [13],
3. Trail making test part B (Trails B) [14],
4. Mini-Mental State Examination (MMSE) [15],
5. Category fluency—animals,
6. Clinical Dementia Rating—Sum of Boxes (CDRSB)
[16], and
7. Functional assessment questionnaire (FAQ).
Baseline covariates considered include age and carriage
of an apolipoprotein E4 (APOE ε4) allele. The PAD popula-
tion includes a total of N5 163 individuals, in which N5 39
(23.9%) were observed to progress to MCI over a median
follow-up time of 4.0 years (interquartile range: 2.1 to
5.6 years; maximum: 11.5 years). Baseline characteristics
of the modeled PAD cohort are presented in Table 1.3. Methods
3.1. Joint mixed-effects model for longitudinal data
To derive a model to simulate plausible data, we first fit a
model to observed ADNI data. We apply a joint (or multivar-
iate) mixed-effects model (JMM) to simultaneously model
continuous longitudinal data for disease markers in the
PAD population. The model respects the within-subject cor-
relation over time and among the battery outcomes.
Linear mixed-effects models are commonly used
to model continuous longitudinal data. The multivariate
mixed-effects model is specified as
yijk 5x0ijk bk 1 b0ik 1b1ik tijk 1εijk for subject i, time j,
and outcome k, where bk are fixed-effect regression coeffi-
cients, and b0ik and b1ik are the subject- and outcome-
specific random intercept and slope. The random effectsare assumed to follow a multivariate Gaussian distribution
with mean vector 0 and variance-covariance matrix S,
with dimension 2p, that is, (b0i1,/,b0ip,b1i1,/,b1ip)
0
wN
(0,S). The model with multivariate random effects has the
advantage of reflecting the dependency within subjects and
among outcomes. The εijk w N ð0; s2kÞ is the residual error.
Because the outcomes are on different scales, we trans-
form the raw outcome measures into a quantile scale ranging
from 0 to 1 (least impaired to most severe dementia). Quan-
tiles are calculated using the empirical cumulative distribu-
tion function using weights that are inversely proportional to
the number of observations from each diagnostic category
for each outcome. The quantiles were then transformed by
the inverse Gaussian quantile function, resulting in an
approximate Z-score before submitting to the model.
When simulating data from these models, the simulated Z-
scores can then be transformed back to the original scale,
which can be integer valued.
Bayesian estimation is performed via Markov Chain
Monte Carlo (MCMC) sampling using the stan_mvmer
function in R package Rstanarm [17].3.2. Random forest algorithm for diagnosis of MCI
To simulate a clinician’s diagnosis of MCI or dementia,
we first use ADNI data to learn an algorithm to approximate
this decision. The random forest algorithm [18] is an
ensemble learning method for classification and regression.
In our application, clinician diagnosis of normal cognition
versus MCI or dementia is the binary outcome variable,
and the seven continuous markers, age, and education are
the predictors. The model is fit using the R package random-
Forest [19]. The fitted model is then applied to simulated
continuous outcomes to predict a clinician’s diagnosis.3.3. Competing clinical trial models for continuous and
time-to-event outcomes in simulation study
The simulated treatment effect on time to progression is
modeled by the Cox proportional hazards model. For the
PACC, we consider MMRM and the cLDA proposed by
Liang and Zeger [9]. Similar to most likelihood-based ap-
proaches for longitudinal data, all three models assume
any missing data are missing at random (MAR).
The version of the PACC used in the study is a composite
of four assessments: ADASDWR, LogMem, log transforma-
tion of Trails B, and MMSE. Each of the four component
scores is first centered by subtracting the baseline sample
mean and then divided by the baseline sample standard de-
viation of that component, to form standardized Z scores.
These Z scores are averaged to form the composite.
The MMRM models treat change from baseline in the
PACC score as the outcome and baseline PACC as a predic-
tor. It treats time as a categorical variable, which allows gen-
eral mean trends in each group. MMRM has been
extensively used for testing treatment effects at specific
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evaluated at a fixed and relatively small number of time
points [20]. In our simulation study, the within-subject
dependence is modeled by a first-order autoregressive
covariance structure.
We also explore models that treat time as a continuous
variable. In cLDA, the baseline outcome is treated as a
response variable rather than a covariate, and the two ran-
domized groups are constrained to have the same mean at
baseline [21,22]. We explore models with linear or
quadratic time trends for each group.3.4. Simulation setup
We conducted a simulation study to evaluate the perfor-
mance of the competing models described in Section 3.3.
In each of 1000 simulated clinical trials with visits every
6 months from 0 to 8 years, a total of 1000 and 1500 patients
are, respectively, randomized to either treatment or placebo
in 1:1 ratio. We also assume the proportion of MCI progres-
sors to be 24% (based on ADNI data, as noted previously).
For the placebo group, no changes will be made to the
JMM fit to ADNI. For the treatment group, we will impose
large (40% improvement on rate of change over the control),
moderate (30% improvement), small (20% improvement),
and no (same as the control) treatment effects on all out-
comes.
To simulate nonignorable missing data, three dropout cat-
egories are considered: intolerability, inefficacy, and missing
completed at random (MCAR). Participants having intolera-
bility or inefficacy drop out from the study immediately after
six and twelve months, respectively. For MCAR, we assume
linear attrition rate of 5% per year for both the treatment and
placebo groups. The simulated dropout rates are described in
Table 2.
To assess bias due to missing data, we simulate complete
data for every subject. The complete data are appropriately
censored for the analysis of “observed” data and left uncen-
sored for analysis of the “complete” data. Completers and
MCAR dropouts are assumed to have the same longitudinal
mean profile within each treatment arm. Dropouts due to
intolerability are simulated to have the expected benefit,
on average, until dropout, followed by an “unobserved”
benefit that is diminished by a factor of 15%. Dropouts
due to inefficacy are simulated to have no benefit.
The four competing clinical trial models are MMRM,
cLDA1 (linear) and cLDA2 (quadratic) for continuous
PACC scores, and Cox for time to progression, with two
baseline covariates namely age at baseline and carriage of
the APOE ε4 allele. The Cox model will use all data
observed up to 8 years until the last subject reaches the final
scheduled visit under the common close design. We assume
a linear enrollment rate such that enrollment is completed
in 4 years and about half the subjects contribute “extra”
common close follow-up in the 4.5- to 8-year range to the
Cox model. The MMRM, cLDA1, and cLDA2 will onlyuse data up to last scheduled visit, that is, from 0 to
4.5 years.
We focus on “treatment policy” estimands of interest. The
estimand will be the difference between randomized groups
in the intention-to-treat population in terms of (1) rate (haz-
ard ratio) of progression to MCI/dementia (Cox); (2) group
difference in PACC at the final study time point (MMRM
and cLDA1); or (3) area between mean PACC curves
(cLDA2). We show how to carry out the hypothesis test of
case (III) in the Supplementary Material. Let Yijk denote
the simulated PACC scores for subject i randomized to group
j at time point k, where i5 1,/,nj , j5 D,P, and k5 1,/,T.
And k 5 0 represents the baseline time point, D is the treat-
ment group, and P is the placebo group. Under MMRM and
cLDA1, for example, the objective is to estimate the
between-treatment difference d 5 mP 2 mD, where m j5 E
(YijT 2 Yij0). A two-tailed test H0:d 5 0 versus H1:ds0 is
carried out to evaluate whether treatment is different from
placebo.
For each simulated data set, we apply all four competing
models to calculate point estimates of d using the observed
data (i.e., dobs) and the complete data (i.e., dcomp). For
each model, “bias” is calculated as the median of the 1000
point estimates of dobs minus dcomp; “bias in percent” is
computed as the median of the 1000 point estimates of
dobs minus dcomp and then divided by dcomp. The interquar-
tiles Q1 and Q3 are also summarized.
In a real clinical trial, the endpoint is measured for com-
pleters but is missing for those who either drop out from the
study either because of inefficacy or intolerability or those
who remain in the study after initiating rescue medication.
Mehrotra et al. [23] discussed that the commonly used
MMRM with the embedded MAR assumption can deliver
an exaggerated estimate of the aforementioned estimand of
interest, in favor of the drug. This happens, in part, due to im-
plicit imputation of an overly optimistic mean for dropouts
in the treatment group. To remedy this, they proposed a
formula-based two-step approach by treating the true
endpoint distribution for treatment group as a mixture of dis-
tributions (one each for the completers and dropouts) rather
than a single distribution. Their approach reduces the bias
associated with the traditional MMRM while maintaining
power. To increase the precision in estimating d, we apply
their method to MMRM, cLDA1, and cLDA2 models in
the simulation study.4. Results
4.1. JMM and random forest fit to ADNI data
We fit a JMM for PAD participants who were observed to
progress to MCI and a separate JMM for those who did not
progress. Seven outcome measures described in Section 2
are included in the model. Fixed-effect covariates for each
outcome include age at baseline and carriage of the APOE
ε4 allele. Three parallel Markov chains are run for 4000
Table 3
Posterior estimates (means and 95% CIs) of the fixed-effect covariates for the joint mixed-effect model fit to seven outcomes for stable and MCI progressor
subpopulations
Parameter
Progressor (N 5 39) Stable (N 5 124)
Mean (95% CI Mean (95% CI
ADAS delayed word recall
Intercept 28.244 (215.39, 21.451) 24.913 (27.755, 22.003)
Year 0.330 (0.189, 0.464) 0.064 (0.021, 0.108)
Age 0.110 (0.021, 0.201) 0.062 (0.023, 0.100)
APOE ε4 0.572 (20.319, 1.437) 0.218 (20.247, 0.670)
Logical memory paragraph recall
Intercept 26.897 (215.425, 0.905) 21.840 (24.983, 1.350)
Year 0.261 (0.136, 0.395) 0.033 (20.084, 0.016)
Age 0.096 (20.005, 0.206) 0.020 (20.023, 0.062)
APOE ε4 0.039 (20.959, 1.099) 0.465 (20.044, 0.985)
Trails B
Intercept 29.458 (214.898, 23.918) 26.364 (29.020, 23.792)
Year 0.353 (0.252, 0.445) 0.022 (20.028, 0.073)
Age 0.124 (0.051, 0.193) 0.084 (0.050, 0.119)
APOE ε4 0.141 (20.540, 0.858) 0.622 (0.187, 1.087)
MMSE
Intercept 0.852 (2191.780, 185.973) 21.385 (275.020, 72.568)
Year 0.009 (23.918, 4.011) 0.022 (22.590, 2.698)
Age 0.007 (22.432, 2.436) 0.020 (20.903, 0.944)
APOE ε4 0.040 (21.116, 11.346) 0.115 (25.683, 5.900)
Category fluency—animals
Intercept 1.430 (2127.590, 130.195) 0.942 (296.958, 98.426)
Year 0.047 (22.910, 2.786) 0.025 (23.399, 3.798)
Age 20.009 (21.658, 1.606) 20.011 (21.224, 1.211)
APOE ε4 0.036 (28.234, 8.775) 20.118 (27.911, 7.920)
CDRSB
Intercept 26.537 (2364.967, 344.177) 1.094 (282.421, 76.732)
Year 0.082 (27.263, 6.390) 0.006 (22.853, 2.947)
Age 0.081 (24.230, 4.517) 20.011 (21.006, 1.027)
APOE ε4 20.224 (220.697, 19.566) 0.117 (25.925, 6.358)
FAQ
Intercept 3.458 (2380.068, 367.151) 0.261 (232.960, 32.991)
Year 0.023 (27.838, 7.140) 0.0007 (21.1420, 1.1710)
Age 20.002 (24.487, 4.718) 20.003 (20.410, 0.449)
APOE ε4 0.343 (222.127, 22.506) 0.014 (22.667, 2.525)
Abbreviations: ADAS, Alzheimer’s Disease Assessment Scale; APOE, apolipoprotein E;MMSE,Mini-Mental State Examination; CDRSB, Clinical Demen-
tia Rating—Sum of Boxes; FAQ, functional assessment questionnaire; SD, standard deviation; CI, credible interval; MCI, mild cognitive impairment.
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carded. Every fourth value of the remaining part of each
chain is stored to reduce correlation, yielding a total of
1500 samples for posterior analysis. Table 3 shows the pos-
terior means and 95% credible intervals of the covariate-
effect parameters. Fig. 1 shows the subject-level observa-
tions and predictions according to time in years of the seven
markers for all individuals, in which the blue and red curves
are estimated using the locally estimated scatter plot
smoother. The bottom panel shows that the predictions pro-
vide reasonable trends of the observations. The posterior es-
timates from JMM will be later used as the true parameter
values to simulate the panel of continuous markers.
For the random forest, 500 trees are fitted, and the number
of variables selected at each split is 3. The node impurity of
each tree is measured by the Gini index. The results show
that CDRSB, LogMem, and FAQ are three most important
outcomes for determining the diagnosis of MCI. The modelhas a 6.19% out-of-bag error rate and 93.81% out-of-bag ac-
curacy rate. Using the fitted random forest, the simulated
cognitive status can be obtained from the simulated contin-
uous markers. Fig. 2 shows the Kaplan-Meier estimated pro-
gression rate of the ADNI-PAD population (black solid line)
along with the progression rate from one large simulated pla-
cebo group (red dots). The simulated progression yields
closer concordance with the Kaplan-Meier estimates at the
earlier stage. Although we observe discrepancies between
the two lines in the middle and the right tail, the red line still
lies within the 95% confidence intervals. Both the subject-
level trajectories and the progression rate illustrate that the
simulated data plausibly mimic the observed data.4.2. Simulation results
Fig. 3 shows the results of one simulated clinical trial with
a 20% treatment effect and sample size n5 1000. The figure
TrailsB
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Fig. 1. Observed (upper panel) and predicted (lower panel) longitudinal profiles of the seven markers for all individuals. Bold lines are locally estimated scatter
plot smoother. Abbreviations: ADASDWR, Alzheimer’s Disease Assessment Scale delayed word recall; MMSE, Mini-Mental State Examination; CDRSB,
Clinical Dementia Rating—Sum of Boxes; FAQ, functional assessment questionnaire.
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different models.
Simulated power and type I error are summarized in
Table 4. Under the null hypothesis (no treatment effect),0.3
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the time-to-progression to mild cognitive impairment or dementia for the two gro
Preclinical Alzheimer’s Cognitive Composite; cLDA, constrained longitudinal dathe MMRM exhibits smaller-than-expected type I error
(about 2%), whereas the other models are closer to the ex-
pected 5% error rate. The Cox model consistently exhibits
the weakest power of the four models. MMRM has the
next best performance, followed by the quadratic
(cLDA2) and linear (cLDA1) models. For example, with
a trial of sample size N 5 1000 subjects of drug with a
30% treatment effect, the simulated power is 33% for
Cox, 79% for MMRM, 86% for cLDA2, and 96% for
cLDA1. In comparing analysis of complete versus
observed data, it seems the missing data do not increase
type I error, but they do inflate power. This suggests the
bias is only an issue with an effective drug, in which
case the effectiveness might appear inflated. Fig. 4 shows
the powers in all scenarios.
Tables 5 and 6 further examine the bias induced by the
missing data pattern. The tables summarize the median
and interquartile ranges (Q1, Q3) of the bias on the PACC
scale (Table 5) and as a percent of effect seen in complete
data [6]. The Cox model seems to have smaller bias with
20% treatment effect, but as the treatment grows, the bias
is comparable for all models. The method proposed by0.3
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Table 4
Power and type I error from 1000 simulated clinical trials
Sample
size Treatment
Observed data Completed data
MMRM cLDA1 cLDA2 Cox PH MMRM cLDA1 cLDA2 Cox PH
1000 0% 0.021 0.051 0.053 0.040 0.027 0.049 0.057 0.046
20% 0.404 0.702 0.502 0.188 0.298 0.564 0.402 0.159
30% 0.794 0.957 0.856 0.322 0.666 0.897 0.751 0.274
40% 0.970 0.999 0.981 0.496 0.907 0.990 0.947 0.425
1500 0% 0.024 0.042 0.054 0.058 0.014 0.048 0.051 0.055
20% 0.560 0.843 0.660 0.261 0.454 0.722 0.550 0.232
30% 0.927 0.996 0.954 0.452 0.847 0.973 0.907 0.392
40% 1.000 1.000 1.000 0.653 0.994 1.000 0.996 0.573
NOTE. The rows with 0% treatment effect simulate the type I error, which we expect to be near 5%.
Abbreviations: MMRM, mixed models of repeated measures; cLDA, constrained longitudinal data analysis; PH, proportional hazards.
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bias, for example, from 27% in favor of treatment to
24.4% in favor of placebo for MMRM with 20% treatment
effect. The method appears to overcorrect the bias in favor of
placebo in these simulations.5. Discussion
We use Bayesian JMM fit using ADNI data to simu-
late correlated longitudinal data that might plausibly arise
in a PAD clinical trial. We used a random forest algo-
rithm, also fit using ADNI, to algorithmically diagnose
MCI in the simulated data so that we could compareSample size: 1000
0 20% 30% 40%
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Trea
Po
w
e
r
Fig. 4. Statistical power for the MMRM, cLDA, and Cox proportional hazards m
sizes of n5 1000 (left panel) and n5 1500 (right panel). Solid lines indicate powe
dashed lines indicate power that would be achieved with complete data (including
greater power with fewer observations because the nonignorable missingness induc
repeated measures; cLDA, constrained longitudinal data analysis; PH, proportionmodels of the PACC to the Cox model of time to pro-
gression. The models of PACC consistently provide at
least twice the power of the Cox model even when the
Cox model has the benefit of considerably more
follow-up visits under a common close design. Given
this inefficiency, the time-to-progression analysis should
be avoided in PAD.
Some might still argue that the clinical meaningfulness of
the time to progression is worth the cost of a larger, longer
trial. However, given that the random forest provided a
purely algorithmic diagnosis with 93.81% out-of-bag accu-
racy, it is suggested that there is minimal additional value
in the diagnosis. And again, while the progression outcomeSample size: 1500
0 20% 30% 40%
tment
MMRM
cLDA linear
cLDA quadratic
Cox PH
Observed data
Completed data
odel for treatment effects 0% (type I error), 20%, 30%, and 40% for sample
r estimates for data observed after simulated nonignorable missingness, and
observations that would be unobserved in reality). The observed data show
es a bias in favor of the treatment. Abbreviations: MMRM, mixed models of
al hazards.
Table 5
Bias of the treatment effect due to missingness
Sample size Analysis method
20% 30% 40%
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
1000 MMRM 0.018 (0.006, 0.031) 0.028 (0.015, 0.040) 0.037 (0.024, 0.049)
cLDA1 0.019 (0.009, 0.029) 0.028 (0.018, 0.038) 0.038 (0.028, 0.048)
cLDA2 0.038 (0.011, 0.065) 0.058 (0.030, 0.084) 0.077 (0.050, 0.104)
Cox PH 20.033 (20.074, 0.010) 20.045 (20.086, 20.001) 20.059 (20.102, 20.017)
MMRM-Mehrotra 20.001 (20.015, 0.012) 20.002 (20.016, 0.011) 20.003 (20.017, 0.010)
cLDA1-Mehrotra 20.001 (20.011, 0.008) 20.001 (20.012, 0.007) 20.003 (20.012, 0.007)
cLDA2-Mehrotra 20.006 (20.034, 0.022) 20.010 (20.038, 0.018) 20.014 (20.042, 0.014)
1500 MMRM 0.018 (0.006, 0.028) 0.027 (0.016, 0.037) 0.036 (0.025, 0.047)
cLDA1 0.018 (0.010, 0.026) 0.027 (0.019, 0.036) 0.037 (0.028, 0.045)
cLDA2 0.037 (0.013, 0.061) 0.056 (0.032, 0.080) 0.075 (0.052, 0.099)
Cox PH 20.028 (20.064, 0.005) 20.042 (20.076, 20.009) 20.055 (20.090, 20.021)
MMRM-Mehrotra 20.002 (20.012, 0.009) 20.003 (20.013, 0.008) 20.004 (20.015, 0.007)
cLDA1-Mehrotra 20.001 (20.009, 0.006) 20.002 (20.010, 0.005) 20.003 (20.011, 0.004)
cLDA2-Mehrotra 20.008 (20.028, 0.015) 20.012 (20.032, 0.011) 20.016 (20.035, 0.007)
Abbreviations: MMRM, mixed models of repeated measures; cLDA, constrained longitudinal data analysis; PH, proportional hazards.
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group-level result is still quantitative (e.g., a hazard ratio)
and requires additional interpretation to assign clinical
meaning.
One might also argue that clinical diagnosis cannot be
adequately modeled algorithmically using trial data. That
is, clinical assessment and diagnosis by a trial-site clini-
cian may consider information not captured by trial mea-
sures. However, the cognitive, clinical, and functional
assessments are designed to capture the relevant informa-
tion, and clinicians generally rely on similar information
obtained through less structured assessments. It seems
questionable that a site clinician will gain much reliable
information beyond the assessments; indeed, this is theTable 6
Bias in percent (%) of the treatment effect due to missingness based on 1000 simu
Sample size Analysis method
20%
Median (Q1, Q3)
1000 MMRM 27.1 (7.0, 52.3)
cLDA1 29.6 (12.4, 51.9
cLDA2 24.5 (5.5, 50.2)
Cox PH 17.4 (216.1, 55
MMRM-Mehrotra 24.4 (223.2, 20
cLDA1-Mehrotra 21.7 (216.2, 15
cLDA2-Mehrotra 26.0 (221.2, 15
1500 MMRM 27.5 (9.7, 52.8)
cLDA1 29.1 (15.7, 48.4
cLDA2 24.8 (8.8, 45.6)
Cox PH 18.0 (28.2, 46.9
MMRM-Mehrotra 23.0 (219.4, 17
cLDA1-Mehrotra 22.1 (213.5, 11
cLDA2-Mehrotra 26.1 (218.8, 12
Abbreviations: MMRM, mixed models of repeated measures; cLDA, constrainjustification for central expert panel adjudication of site
diagnoses.
The Bayesian joint models are well suited to simulating
plausible panels of correlated longitudinal data necessary
to compare clinical trial designs. This approach could be
useful in many other contexts where one is interested in a
fair comparison of different outcome measures, different
combinations of correlated outcomes, or different models
of treatment effect. Simulations that ignore the correlations
among important outcomes will likely not provide reliable
comparisons.
All the models considered were susceptible to bias
induced by a plausible missing data pattern. However,
this bias seemed to only affect scenarios with an effectivelated trials for the given sample size, treatment effect, and analysis method
30% 40%
Median (Q1, Q3) Median (Q1, Q3)
29.9 (16.3, 46.8) 29.6 (19.4, 42.3)
) 29.8 (18.9, 43.7) 29.7 (21.4, 39.7)
26.5 (13.7, 42.6) 26.2 (16.5, 37.9)
.0) 22.2 (24.5, 52.7) 25.5 (5.2, 50.4)
.6) 22.9 (215.9, 13.3) 22.8 (212.7, 8.6)
.4) 21.7 (211.3, 9.1) 22.0 (29.2, 5.7)
.9) 24.5 (215.5, 9.4) 24.7 (213.0, 5.2)
28.2 (16.6, 43.3) 28.3 (19.6, 39.3)
) 29.2 (19.9, 40.9) 29.3 (22.2, 37.8)
25.4 (15.2, 38.2) 25.5 (17.8, 34.6)
) 22.7 (3, 46.3) 24.3 (8.6, 44.6)
.6) 23.0 (213.8, 9.7) 23.1 (211.2, 6.2)
.4) 22.3 (29.8, 5.7) 22.4 (27.9, 3.5)
.7) 25.5 (213.9, 5.7) 25.5 (211.5, 2.8)
ed longitudinal data analysis; PH, proportional hazards.
D. Li et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 308-318 317treatment and did not inflate type I error under the null hy-
pothesis. The Mehrotra method shows promise in correct-
ing this bias, but it might overcorrect in favor of placebo,
and it would be impossible to detect this overcorrection in
practice. Given that type I error is not inflated, we are in-
clined to suggest no change to the status quo approach in
which the primary analysis is based on likelihood-based
methods which are robust to MAR and applying appro-
priate MNAR sensitivity analyses such as the delta
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1. Systematic review: Donohue et al. (2011) explored
the relative efficiency of time-to-event versus
continuous outcomes, reviewed the literature,
derived an analytic calculation of the relative effi-
ciency, and simulated trials in mild cognitive
impairment (MCI) populations. The current work
extends this earlier work to the preclinical Alz-
heimer’s population. We reviewed trials in preclini-
cal Alzheimer’s disease on clinicaltrials.gov and
found that most use a continuous primary outcome
but at least one is using time to MCI.
2. Interpretation: The simulation study confirms that
continuous outcomes provide about twice the statis-
tical power to detect treatment effects compared
with time to MCI. Plausible scenarios of attrition
due to intolerability and perceived lack of efficacy
inflate estimates of treatment benefit, although type
I error is not inflated.
3. Future directions: The novel simulation methodol-
ogy using hierarchical Bayesian mixed-effect
models of multiple outcomes and random forests
can be used to optimize preclinical Alzheimer’s
clinical trial efficiency and power and to minimize
bias.References
[1] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM,
et al. Toward defining the preclinical stages of Alzheimer’s disease:
Recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s dis-
ease. Alzheimer’s Demen 2011;7:280–92.
[2] Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M,
Salmon DP, et al. The A4 study: StoppingAD before symptoms begin?
Sci Translational Med 2014;6:228fs13.
[3] ClinicalTrials.gov. An efficacy and safety study of atabecestat in
participants who are asymptomatic at risk for developing Alzheimer’s
dementia (EARLY), Tech. rep., National Library of Medicine (US),
Bethesda, MD (2015 Oct 6 - 2019 Jan 21), https://clinicaltrials.gov/
ct2/show/NCT02569398. Accessed January 2019.
[4] Caputo A, Racine A, Paule I, Martens EP, Tariot P, Langbaum JB, et al.
Rationale for selection of primary endpoints in the Alzheimer Preven-
tion Initiative Generation study in cognitively healthy APOE4 homo-
zygotes, Alzheimer’s & Dementia. J Alzheimer’s Assoc 2017;
13:P1452.
[5] Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R,
Thomas RG, et al. The preclinical Alzheimer cognitive composite:
Measuring amyloid-related decline. JAMA Neurol 2014;71:961–70.
[6] Cox DR. Regression models and life-tables. J R Statis-tical Soc Ser B
(Methodological) 1972;34:187–202.
D. Li et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 308-318318[7] Donohue M, Gamst A, Thomas R, Xu R, Beckett L, Petersen R,
et al. The relative efficiency of time-to-threshold and rate of
change in longitudinal data. Contemp Clin Trials 2011;
32:685–93.
[8] Mallinckrodt CH, Sanger TM, Dube S, DeBrota DJ, Molenberghs G,
Carroll a J, et al. Assessing and interpreting treatment effects in longi-
tudinal clinical trials with missing data. Biol Psychiatry 2003;
53:754–60.
[9] Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and
discrete responses for pre-post designs, Sankhya. Indian J Stat Ser B
2000;62:134–48.
[10] Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC,
Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudi-
nal cognitive decline. Ann Neurol 2012;72:578–86.
[11] Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW,
Aisen PS. Association between elevated brain amyloid and subsequent
cognitive decline among cognitively normal persons. JAMA 2017;
317:2305–16.
[12] Mohs RC, Cohen L. Alzheimer’s Disease Assessment Scale (ADAS).
Psychopharmacol Bull 1988;24:627.
[13] Wechsler D. WMS-R: Wechsler Memory Scale-Revised, The
Psychological Corporation, San Antonio, TX; 1987.
[14] Tombaugh TN. Trail Making Test A and B: Normative data stratified
by age and education. Arch Clin Neuropsychol 2004;19:203–14.[15] Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res 1975;12:189–98.
[16] Morris JC. The Clinical Dementia Rating (CDR): current version and
scoring rules. Neurology 1993;43:2412–4.
[17] Goodrich B, Gabry J, Ali I, Brilleman S. Rstanarm: Bayesian applied
regression modeling via Stan, R package version 2.17.4, http://
mc-stan.org/, 2018. Accessed January 2019.
[18] Breiman L. Random forests. Machine Learn 2001;45:5–32.
[19] Liaw A, Wiener M. Classification and regression by randomForest. R
News:18–22, https://CRAN.R-project.org/doc/Rnews/.
[20] Siddiqui O, Hung HJ, O’Neill R. MMRMvs. LOCF: A comprehensive
comparison based on simulation study and 25 nda datasets. J Biopharm
Stat 2009;19:227–46.
[21] Liu GF, Lu K, Mogg R, MallickM, Mehrotra DV. Should baseline be a
covariate or dependent variable in analyses of change from baseline in
clinical trials? Stat Med 2009;28:2509–30.
[22] Lu K. On efficiency of constrained longitudinal data analysis versus
longitudinal analysis of covariance. Biometrics 2010;66:891–6.
[23] Mehrotra DV, Liu F, Permutt T. Missing data in clinical trials: Control-
based mean imputation and sensitivity analysis. Pharm Stat 2017;
16:378–92.
[24] Rubin DB. Formalizing subjective notions about the effect of nonre-
spondents in sample surveys. J Am Stat Assoc 1977;72:538–43.
